Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications

被引:37
作者
dos Santos, Giovanny Carvalho [1 ]
Martins, Lucas Michelao [2 ]
Bregadiolli, Bruna Andressa [2 ]
Moreno, Vitor Fernandes [1 ]
da Silva-Filho, Luiz Carlos [1 ]
Sacoman Torquato da Silva, Bruno Henrique [3 ]
机构
[1] Sao Paulo State Univ UNESP, Sch Sci, Dept Chem, Bauru, SP, Brazil
[2] Sao Paulo State Univ UNESP, Inst Chem, Araraquara, SP, Brazil
[3] Fed Univ Uberlandia UFU, Inst Chem, BR-38408144 Uberlandia, MG, Brazil
基金
巴西圣保罗研究基金会;
关键词
antiviral; heterocycles; SAR; synthesis; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; IN-VITRO; EBOLA-VIRUS; PROTEASE INHIBITORS; FAVIPIRAVIR T-705; DOUBLE-BLIND; RIBAVIRIN; IVERMECTIN; SPECTRUM;
D O I
10.1002/jhet.4349
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
A virus outbreak challenges the economic, medical, and public health infrastructure worldwide. More than one virus capable of triggering diseases have been identified per year since 1972, which requires the development of new ways of treatment and prevention, however, such processes are not rapid and easy. With the pandemic scenario experienced since early 2020, several drugs with well-known purposes have gained prominence, due to speculation of their use in the treatment against the new coronavirus. Among the main drugs studied, the vast majority contain a heterocyclic structure. In this review, we presented the traditional and efficient synthesis of 15 drugs that have been studied for the COVID-19 treatment, containing in their structure heterocycles like indole, quinoline, pyrimidone, tetrahydrofuran, pyrrolidine, triazole, pyridazine, pyrazole, pyrrolopyrimidine, azetidine, pyrrolotriazine, pyrazine, tetrahydropyran, benzofuran, spiroketal, and thiazole. Furthermore, we have shown the original applications, as well as their structure-activity relationship and what is their situation as a drug candidate against COVID-19. Thus, the objective was to consolidate the main synthetic and pharmacological aspects involving clinically developed heterocycles that at some point were presented as promising against SARS-CoV-2.
引用
收藏
页码:2226 / 2260
页数:35
相关论文
共 244 条
[1]   A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness [J].
Ahmed, Sabeena ;
Karim, Mohammad Mahbubul ;
Ross, Allen G. ;
Hossain, Mohammad Sharif ;
Clemens, John D. ;
Sumiya, Mariya Kibtiya ;
Phru, Ching Swe ;
Rahman, Mustafizur ;
Zaman, Khalequ ;
Somani, Jyoti ;
Yasmin, Rubina ;
Hasnat, Mohammad Abul ;
Kabir, Ahmedul ;
Aziz, Asma Binte ;
Khan, Wasif Ali .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 :214-216
[2]   Baricitinib: A Review in Rheumatoid Arthritis [J].
Al-Salama, Zaina T. ;
Scott, Lesley J. .
DRUGS, 2018, 78 (07) :761-772
[3]   New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 [J].
Aleissa, Muneerah M. ;
Silverman, Emily A. ;
Acosta, Luisa M. Paredes ;
Nutt, Cameron T. ;
Richterman, Aaron ;
Marty, Francisco M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (01)
[4]   Increasing off-label use of antipsychotic medications in the United States, 1995-2008 [J].
Alexander, G. C. ;
Gallagher, S. A. ;
Mascola, A. ;
Moloney, R. M. ;
Stafford, R. S. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) :177-184
[5]   Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19 [J].
Ami, Ei-ichi ;
Ohrui, Hiroshi .
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (04) :510-517
[6]  
Anand N., 1997, PHARM LIBR, V25, P1, DOI 10.1016/S0165-7208(97)80022-0
[7]  
Andersag H., 1941, US Patent, Patent No. [2.233.970, 2233970, 2,233,970]
[8]   Reversal Agent and Linker Variants of Reversed Chloroquines: Activities against Plasmodium falciparum [J].
Andrews, Simeon ;
Burgess, Steven J. ;
Skaalrud, Deborah ;
Kelly, Jane Xu ;
Peyton, David H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (02) :916-919
[9]   Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial [J].
Arabi, Yaseen M. ;
Alothman, Adel ;
Balkhy, Hanan H. ;
Al-Dawood, Abdulaziz ;
AlJohani, Sameera ;
Al Harbi, Shmeylan ;
Kojan, Suleiman ;
Al Jeraisy, Majed ;
Deeb, Ahmad M. ;
Assiri, Abdullah M. ;
Al-Hameed, Fahad ;
AlSaedi, Asim ;
Mandourah, Yasser ;
Almekhlafi, Ghaleb A. ;
Sherbeeni, Nisreen Murad ;
Elzein, Fatehi Elnour ;
Memon, Javed ;
Taha, Yusri ;
Almotairi, Abdullah ;
Maghrabi, Khalid A. ;
Qushmaq, Ismael ;
Al Bshabshe, Ali ;
Kharaba, Ayman ;
Shalhoub, Sarah ;
Jose, Jesna ;
Fowler, Robert A. ;
Hayden, Frederick G. ;
Hussein, Mohamed A. .
TRIALS, 2018, 19
[10]   Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking [J].
Arouche, Tiago da Silva ;
Reis, Arthur Ferreira ;
Martins, Anderson Yuri ;
Costa, Jose Francisco S. ;
Carvalho Junior, Raul Nunes ;
Neto, Antonio Maia J. C. .
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2020, 20 (12) :7311-7323